


RealRate

PHARMACEUTICAL 2018

UNITED THERAPEUTICS Corp Rank 42 of 342





United Therapeutics



PHARMACEUTICAL 2018



RealRate

UNITED THERAPEUTICS Corp Rank 42 of 342

The relative strengths and weaknesses of UNITED THERAPEUTICS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UNITED THERAPEUTICS Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 105% points. The greatest weakness of UNITED THERAPEUTICS Corp is the variable Other Expenses, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 178% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	1,447,900
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	444,700
Liabilities, Non-Current	63,700
Other Assets	885,800
Other Compr. Net Income	-2,800
Other Expenses	667,300
Other Liabilities	250,000
Other Net Income	-45,400
Other Revenues	1,725,300
Property and Equipment	545,700
Research and Development	264,600
Selling, General and Administrative Expense	330,100

Output Variable	Value in 1000 USD
Assets	2,879,400
Liabilities	758,400
Expenses	1,262,000
Revenues	1,725,300
Stockholders Equity	2,121,000
Net Income	417,900
Comprehensive Net Income	416,500
Economic Capital Ratio	223%

